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Abstract The goal of this study was to compare the
efficacy and toxicity of chemotherapy to exemestane plus
everolimus (EXE/EVE) through a network meta-analysis
(NMA) of randomized controlled trials. NMA methods
extend standard pairwise meta-analysis to allow simulta-
neous comparison of multiple treatments while maintaining
randomization of individual studies. The method enables
‘‘direct’’ evidence (i.e., evidence from studies directly
comparing two interventions) and ‘‘indirect’’ evidence (i.e.,
evidence from studies that do not compare the two inter-
ventions directly) to be pooled under the assumption of
evidence consistency. We used NMA to evaluate progres-
sion-free survival (PFS) and time to progression (TTP)
curves in 34 studies, and response rate (RR) and the hazard
ratios (HRs) of the PFS/TTP in 36 studies. A number
needed to treat (NNT) analysis was also performed as well
as descriptive comparison of reported toxicities. The NMA
for PFS/TTP curves and for HR shows EXE/EVE is more
efficacious than capecitabine plus sunitinib, CMF, mege-
strol acetate and tamoxifen, with an average of related-
PFS/TTP difference ranging from about 10 months for
capecitabine plus sunitinib to more than 6 months for
tamoxifen. The NMA for overall RR shows that EXE/EVE
provides a better RR than bevacizumab plus capecitabine,
capecitabine, capecitabine plus sorafenib, capecitabine plus
sunitinib, CMF, gemcitabine plus epirubicin plus pacli-
taxel, EVE plus tamoxifen, EXE, FEC, megestrol acetate,
mitoxantrone, and tamoxifen. Finally, the NMA for NNT
shows that EXE/EVE is more beneficial as compared to
BMF, capecitabine, capecitabine plus sunitinib, CMF,
FEC, megestrol acetate, mitoxantrone, and tamoxifen. The
combination of EXE/EVE as first- or second-line therapy
for ER?ve/HER2-ve metastatic breast cancer is more
efficacious than several chemotherapy regimens that were
reported in the literature. Toxicities also favored EXE/EVE
in most instances.
Keywords Metastatic breast cancer ! Exemestane !
Everolimus ! Network meta-analysis ! Progression-free
survival ! Response rate ! Chemotherapy
Introduction
Many improvements have been made in the treatment of
hormone receptor (HR)?ve metastatic breast cancer
(MBC) in the past 15 years. Novel aromatase inhibitors
(AIs) and drugs that target specific pathways (i.e., mTOR
and CDK4/6 inhibitors) become available, and new
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chemotherapies were introduced (ixabepilone and eribulin)
along with highly effective HER2-targeted combination
therapies for HER2?ve cancers including the HR?ve/
HER2?ve tumors. These novel therapies improved
response rates (RRs) and increased median progression-
free survival (PFS) with variable but often modest or added
toxicity [1, 2]. The preponderance of first-line treatment
options also poses challenges on how to sequence the
several effective therapies. Based on data from the
BOLERO-2 trial, the mTOR inhibitor everolimus (EVE) in
combination with exemestane (EXE) was approved by the
US Food and Drug Administration and European Medici-
nes Agency to treat postmenopausal women with HR?ve/
HER2-ve advanced breast cancer that recurred or pro-
gressed during or after a non-steroidal AI therapy [3]. The
combination of EXE/EVE has doubled the median PFS
compared to EXE/placebo at 18 months median follow-up,
with good health-related quality of life (HRQoL), and a
consistent efficacy in all predefined patient subgroups (i.e.,
visceral metastases, patients with bone disease, and elderly
patients) [4–6]. Moreover, the improvement on PFS by the
EXE/EVE has been also confirmed into the final analysis
performed by Yardley et al. [4]. However, several
chemotherapy regimens exist that also produce substantial
clinical benefit as first-line therapy for HR?ve MBC. In
some instances, for example, in patients with extensive
visceral metastasis, chemotherapy can even be considered
as the preferred option [7–11]. Up to now, chemotherapy
has not been compared with endocrine therapy in combi-
nation with targeted therapy (e.g., EXE/EVE) as first-line
treatment for MBC in randomized trials; only two trials are
ongoing comparing endocrine therapy plus a target agent
(EVE or palbociclib) versus capecitabine (see: www.clin
icaltrial.gov), but the data are not ready yet. However, a
trial including exclusively patients in first line for MBC is
unlikely to be performed. Furthermore, there is no single
optimal first-line chemotherapy for MBC in general and
choice of drugs depends on patient characteristics, prior
treatment variables, and patients preference. The purpose
of this study was to perform a network meta-analysis
(NMA) of the existing literature to indirectly compare the
efficacy and safety of EXE/EVE with chemotherapy agents
as first or second-line therapy for HR?ve MBC.
Methods
Health care decision makers are often faced with the
challenge of assessing competing interventions in the
absence of an randomized controlled trial (RCT) compar-
ing all interventions of interest simultaneously in a head-to-
head fashion. When the available RCTs of interest do not
all compare the same interventions but each trial compares
only a subset of the interventions of interest, it is possible
to develop a network of RCTs where all trials have at least
one intervention in common with another. Such a network
allows for indirect comparisons of interventions not studied
in a head-to-head fashion [18]. Therefore, NMA is a gen-
eralization of standard pairwise meta-analysis that allows
pooling both the direct and indirect evidence available for a
given intervention. Even when direct evidence is available
for some interventions of interest, combining these with
indirect comparisons in a NMA may yield a more refined
and precise estimate for the corresponding relative treat-
ment effects. For these reasons, NMA has become one of
the most important tools used in cost-effectiveness decision
making to effectively exploit all the evidence available for
a given treatment [12–15].
A Bayesian NMA framework was used for each end-
point considered: the tumor RR, the hazard ratio (HR) of
PFS/time to progression (TTP), and the whole PFS/TTP
curve. Additionally, using the results of the latter analysis,
a meta-analysis of the number needed to treat (NNT) was
also performed for EVE plus EXE versus each one of the
other therapies described in the previous sections. The
NNT is the average number of patients needed to be treated
to prevent an adverse outcome in one additional patient
compared to a control treatment group.
An extensive description of the methods used and the
associated references are available in the Supplemental
Material Section.
Results
Among 8910 papers/abstracts evaluated, 44 published
papers were included into the NMA. Non-randomized
studies or studies with insufficient or inconsistent data on
PFS/TTP have been excluded from the analysis. Finally, 34
and 36 studies were considered for the analysis of the entire
PFS/TTP curve and for the analysis of RR and HR of PFS/
TTP, respectively. Unfortunately, in the reported
chemotherapy-based studies the proportion of ER?ve BC
were not specified; moreover in some older studies, the BC
classification with regards to the HER2 signaling is not
described, thus including also HER2?ve patients. The
characteristics of each study design are listed in Tables 1
and 2. All patients included have ER?ve/HER2-ve MBC
in their first or second line of treatment. To create the
network for the comparison of the EXE/EVE combination
with the chemotherapy-based regimes, we decided to
include the paper published by Dixon et al. [16] (even
though published in 1992), as it is the only study available
which compared endocrine therapy versus chemotherapy in
MBC with regards to PFS/TTP and RR/HRs of PFS/TTP,
respectively (Fig. 1a, b).
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Table 1 Key studies’ characteristics of the trials included into the analyses
First author Year Treatment N pts/
arm
Centers Follow-up Median
TTP or
PFS
(months)
Ackland [42] 2001 FEC 223 48 in 20 countries Median FUP of more than
20 months
TTP 8.9
CMF 237 TTP 6.3
Albain [43] 2008 GEM ? PAC 266 98 NA TTP 6.14
PAC 263 TTP 3.98
Bachelot [44] 2012 EVE ? TAM 54 NA Median follow-up for tamoxifen
plus everolimus 23.7 months; for
tamoxifen alone: 24.2 months
TTP 8.6
TAM 57 TTP 4.5
Bachelot [45] 2011 CAP ? DOC 33 15 Centers in France Median FUP 42 months PFS 12.4
EPI ? DOC 35 PFS 6.8
Baselga [3] 2012 EVE ? EXE 485 189 Centers in 24 countries Median FUP 7.6 months PFS 6.9
EXE 239 PFS 2.8
Baselga [18] 2012 CAP ? SOR 115 Spain, France, and Brazil NA TTP 6.8
CAP 114 TTP 4.1
Bergh [46] 2012 DOC ? SUN 296 127 in 27 countries Median FUP 18 months PFS 8.6
DOC 297 PFS 8.3
Boer [47] 2012 VAN ? DOC 35 13 Centers in 5 countries
(Hungary, South Africa,
Spain, Sweden and
Taiwan)
NA PFS
35 weeks
DOC 29 PFS
24 weeks
Bonneterre [48] 2002 DOC 86 22 30.3 months TTP 6.5
FU ? VIN 90 TTP 5.1
Bonneterre [49] 2004 DOC ? EPI 70 12 Centers in France 23.8 months TTP 7.8
FEC 72 TTP 5.9
Brufsky [50] 2011 PAC ? BEVA 94 39 Centers in the US The median FUP were 14.6 months
for PB and 17.1 months for PB G
PFS 8.8
PAC ? BEVA ? GEM 93 PFS 11.3
Campone [51] 2013 VIN ? CAP 44 Multicenter NA PFS 7.2
VIN -[CAP 47 PFS 3.4
DOC ? CAP 48 PFS 8.9
Chan [52] 2009 GEM ? DOC 153 International, multicenter NA PFS 8.05
CAP ? DOC 152 PFS 7.98
Crown [53] 2013 CAP ? SUN 221 From 105 centers in 18
countries
Median FUP 14.3 months PFS 5.5
CAP 221 PFS 5.9
Del Mastro [54] 2013 GEM ? DOC 118 Multi-center NA TTP 7.74
GEM ? PAC 123 TTP 7.80
Dixon [16] 1992 MA 30 1 NA TTP 5
MITOX 30 TTP 5
Fountzilas [55] 2004 PAC ? EPI 163 NA Median FUP 23.5 months TTP 8.1
PAC ? CARBO 164 TTP 10.8
Fountzilas [56] 2009 PAC ? CARBO 136 NA Median FUP 34 months TTP 11.5
GEM ? DOC 144 TTP 10.4
PAC weekly 136 TTP 11.4
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Table 1 continued
First author Year Treatment N pts/
arm
Centers Follow-up Median TTP or PFS
(months)
Ghosn [56] 2011 NAV ? CAP 41 Four centers NA TTP 10
DOC 29 TTP 12
Gradishar [57] 2013 PAC ? SOR 119 India, US and Brazil NA PFS 6.9
PAC 118 PFS 5.6
Gradishar
[27, 58]
2012 NAB-PAC
300 mg/m2
76 Multi-centre NA PFS 10.9
NAB-PAC
100 mg/m2
76 PFS 7.5
NAB-PAC
150 mg/m2
74 PFS 14.6
DOC 74 PFS 7.8
Hatschek [59] 2012 EPI ? PAC 143 10 NA PFS 10.8
EPI ? PAC ? CAP 144 PFS 12.4
Heidemann [60] 2002 MITOX 133 NA Median FUP
13.62 months
TTP 4.4
FEC 127 TTP 6.15
Jones [61] 2005 DOC 225 Multi-centre Median FUP
5.1 years
TTP 5.7
PAC 224 TTP 3.6
Kaufmann [62] 2000 EXE 366 144 Centers in 19 countries Median FUP
48.9 weeks
TTP 20.3 weeks
MA 403 TTP 16.6 weeks
Langley [63] 2005 EPI ? PAC 353 62 Centers in the UK and the Republic
of Ireland
NA PFS 7
EPI ? CYC 352 PFS 7.1
Luck [64] 2013 CAP ? PAC 170 63 Centers in Germany and Austria Median FUP
24.9 months
PFS 10.4
EPI ? PAC 170 PFS 9.2
Martin [65] 2011 PAC ? MOT 91 70 Centres from Asia, Europe,
North America, and Oceania
NA PFS 9.5
PLB 94 PFS 9
PAC ? BEVA 97 PFS 11.5
Miles [66] 2010 BEVA 7.5 mg/kg
? DOC
248 NA Median FUP
25 months
PFS 9
BEVA 15 mg/kg
? DOC
247 PFS 10.1
DOC 241 PFS 8.2
Miller [67] 2007 PAC ? BEVA 347 NA Paclitaxel plus
bevacizumab
41.6 months;
paclitaxel
43.5 months
PFS 11.8
PAC 326 PFS 5.9
von Minckwitz
[68]
2005 BMF 162 55 Centers in 4 countries (Belgium,
Bulgaria, Germany, UK)
NA TTP 8.2
CMF 183 TTP 6.7
Norris [69] 2000 DOX ? VIN 151 30 Centers in Canada Median FUP
29 months
TTP 6.2
DOX 149 TTP 6.1
O’Shaughnessy
[70]
2001 CAP 62 23 Centers in US, Canada, Europe,
Australia
NA TTP 4.1
CMF 33 TTP 3
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Network meta-analysis (NMA) of the whole PFS/
TTP curves
The reported Kaplan–Meier curves were digitized to per-
form a NMA involving the whole PFS/TTP curves (Figs.
S1A, S1B). The DIC values for the fixed and random
effects are reported in Table S1. The values showed that
the fractional polynomial model with fixed effects provided
the best fit to the data. The estimated HRs (not reported)
showed that for many treatments the assumption of pro-
portional hazards is not tenable due to the markedly change
of HRs through time, suggesting that the use of this more
flexible methodology is more appropriate than the analysis
based on the HRs alone.
Table 1 continued
First author Year Treatment N pts/
arm
Centers Follow-up Median
TTP or
PFS
(months)
Pajk [71] 2008 CAP 23 Multicenter [9] Median FUP 17 months PFS 2.8
VIN 24 PFS 2.6
Papadimitriou
[72]
2009 DOC 34 NA NA TTP 5.8
DOC ? GEM 41 TTP 6.3
Paridaens [73] 2000 PAC 166 Europe Tumor response was assessed after cycles 3, 5,
and 7, and every 2 months thereafter
PFS 3.9
DOX 165 PFS 7.5
Paridaens [74] 2008 EXE 182 81 Centers Patients were evaluated at baseline; at weeks 8,
16, and 24; then every 12 weeks until week
96; and thereafter every 24 weeks
PFS 9.9
TAM 189 PFS 5.8
Robert [75] 2011 SUN ? PAC 242 109 Centers in 4
countries (Germany,
Italy, Spain, and the
US)
Median FUP 8.1 months PFS 7.4
BEVA ? PAC 243 PFS 9.2
Robert [76] 2011 CAP 206 Multicenter (US) Median FUP 15.6 months for the Cape cohort
and 19.2 months for the TAX/ANTHRA
cohort
PFS 5.7
TAX/ANTHRA 207 PFS 8
BEVA ? CAP 409 PFS 8.6
BEVA ? TAX/
ANTHRA
415 PFS 9.2
Rugo [77] 2013 IXA (16 mg/
m2) ? BEVA
46 Multinational (France,
Italy, UK, USA)
Median FUP of at least 19 months PFS 9.6
IXA (40 mg/
m2) ? BEVA
45 PFS 11.9
PAC ? BEVA 32 PFS 13.5
Stockler [78] 2011 CAP (combined) 216 34 Centers Median FUP 3.3 years PFS 6
CMF 109 PFS 6
Vici [79] 2011 DOC ? GEM 36 Five centers in Italy NA PFS 10.9
DOC ? CAP 36 PFS 10
Yardley [4] 2009 LIP DOX 50 Multicenter (US) NA PFS 6.5
DOC 52 PFS 5.5
Zielinski [80] 2005 GEM ? EPI ? PAC 124 29 Centers in 12
countries
Median FUP 20.4 months TTP 9.1
FEC 135 TTP 9
BMF bendamustine hydrochloride, methotrexate, 5 fluorouracil, CMF cyclophosphamide, methotrexate, 5 fluorouracil, FEC 5 fluorouracil,
epirubicin, cyclophosphamide, NA not available
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In Fig. 2a (and Table S2A), the estimates of the differ-
ence in the expected PFS/TTP between EXE/EVE versus
each single chemotherapy-based treatment are represented.
The estimated PFS/TTP curves were extrapolated up to
60 months.
According to these results, the combination of EVE with
EXE is projected to be more efficacious than either cape-
citabine plus sunitinib, or CMF, or megestrol acetate or
tamoxifen, with an average expected PFS/TTP difference
ranging from about 10 months for capecitabine plus suni-
tinib to slightly more than 6 months for tamoxifen. In
BOLERO-2 trial, the comparison was direct between EVE/
EXE and EXE alone, leading to a difference of PFS of
about 4 months. As regards the combination CAP/SUN, for
example, the NMA incorporates this result in the com-
parison versus EVE/EXE through all the comparisons in
the pathway that links these two treatments (see pathway in
Fig. 1a: EVE/EXE vs. EXE, EXE vs. MA, MA vs.
mitoxantrone, mitoxantrone vs. FEC, CAP vs. CAP/SUN)
leading to the difference of about 10 months of PFS/TTP in
favor of EVE/EXE (in this case, the NMA estimated dif-
ference of PFS/TTP in favor of EVE/EXE vs. CAP/SUN is
higher than the one reported by BOLERO-2 for EVE/EXE
vs. EXE alone but the comparators for EVE/EXE are not
the same).
When compared to other chemotherapies, there is a
trend in favor of EVE plus EXE, although the 95 %
credible intervals, CrIs [17] include zero, suggesting that
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Fig. 1 a Network of the trials inserted into the analysis of the PFS/TTP curves. b Network of the trials inserted into the analysis of the RRs and
the HRs of PFS/TTP
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EVE with EXE is expected to be at least as efficacious as
these alternatives.
Network meta-analysis (NMA) of overall response
rates
For theNMAof theRRs,we used a binomial likelihood for the
number of patients who responded. We used the fixed effects
model as it provided a slightly better fit to the data than the
random effects model (DIC for fixed effects model =
514.021, DIC for random effects model = 515.242). Esti-
mates of the posterior means and medians, together with the
CrIs of the odds ratios of each treatment versus the combi-
nation EVE plus EXE are reported in Fig. 2b and in Table
S2B.
Overall these results suggest that the combination of
EVE plus EXE provides a better RR than bevacizumab
plus capecitabine, capecitabine, capecitabine plus sor-
afenib, capecitabine plus sunitinib, CMF, gemcitabine plus
epirubicin plus paclitaxel, EVE plus tamoxifen, EXE, FEC,
megestrol acetate, mitoxantrone, or tamoxifen. There is no
clear evidence for the other chemotherapy-based treat-
ments to be more efficacious than the combination of EVE
plus EXE.
Network meta-analysis (NMA) of hazard ratios
for PFS/TTP
For the NMA of the HRs, we assumed that the log HRs are
normally distributed with the log HR mean equaling the true
log HR observed in each study and the variance equaling the
observed variability in each study. The fixed effects model
provided a slightly better fit to the data, as confirmed by the
DIC values (2.579 for the fixed and 2.899 for the random
effects model). Figure 2c (and Table S2C) reports the esti-
mates for the posterior means and medians, together with the
80 and 95 % CrIs for the HRs of each treatment versus the
combination EXE/EVE. The results suggest that EVE plus
EXE has lower HRs than capecitabine, capecitabine plus
sunitinib,CMF,EVEplus tamoxifen,EXE,megestrol acetate,
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or tamoxifen. Additionally, there is no clear evidence for the
other chemotherapies to be better than the combination of
EXE/EVE in terms of PFS/TTP HRs.
Network meta-analysis (NMA) of number needed
to treat (NNT)
Based on the estimated PFS/TTP curves from the previous
analysis, we also computed the NNT for EXE/EVE versus
the other chemotherapy-based treatments. We evaluated
the NNT for every month up to 17 months, which was the
maximum follow-up time available in the BOLERO-2 trial
[3]. Figure 3 provides the estimated posterior medians of
the NNT for all months, and it is possible to postulate that
the combination of EXE/EVE produces a permanent pos-
itive NNT, ranging from 1 to about 8, even if for most of
the competing treatments it is below 4. Table 3 reports the
posterior medians and the 95 % CrIs for the NNT of EVE
plus EXE versus each single chemotherapy treatment at 3,
9, and 15 months, respectively. The results suggest that
EVE plus EXE is more beneficial (i.e., it has a positive
NNT) for all the three periods considered with regards to
BMF, capecitabine, capecitabine plus sunitinib, CMF,
FEC, megestrol acetate, mitoxantrone, and tamoxifen.
Additionally, there is also evidence that EVE plus EXE
provides an increased benefit when compared to many of
the remaining treatments in at least one of the three periods
considered. Moreover, there is no clear evidence that the
combination of EXE/EVE is more detrimental than any of
the other treatments.
Risk of bias assessment
The risk of bias assessment for the eligible studies is pre-
sented in Figs. S2 and S3. Eighteen studies were open-label
studies without blinding of patients and personnel. In six
Fig. 2 a NMA results for the PFS/TTP curves. Values reported are
differences in the expected PFS/TTP (in months) for the combination
of everolimus plus exemestane versus each one of the other
treatments. Central dots represent posterior medians, triangles and
crosses represent posterior means, thin lines are 95 % credible
intervals, while thicker ones are 80 % credible intervals. It provides
the posterior means and medians, together with the 80 and 95 % CrIs.
If the 95 % CrI does not include the value 0, this suggests that there is
evidence of a difference between the treatments. The symbol of the
triangle highlights the combination EXE/EVE is significantly supe-
rior. BEVA ? CAP, bevacizumab ? capecitabine; BEVA ? DOC,
bevacizumab 15 mg/kg ? docetaxel; BEVA ? GEM ? PAC, pacli-
taxel ? bevacizumab ? gemcitabine; BEVA ? PAC, beva-
cizumab ? paclitaxel; BMF, bendamustine hydrochloride,
methotrexate, 5 fluorouracil; CAP, capecitabine; CAP ? DOC,
capecitabine ? docetaxel; CAP ? SOR, capecitabine ? sorafenib;
CAP ? SUN, capecitabine ? sunitinib; CMF, cyclophosphamide,
methotrexate, 5 fluorouracil; DOC, docetaxel; DOC ? EPI, doc-
etaxel ? epirubicin; DOC ? GEM, docetaxel ? gemcitabine;
DOC ? SUN, docetaxel ? sunitinib; DOX, doxorubicin; EPI ?
GEM ? PAC, gemcitabine ? epirubicin ? paclitaxel; EVE ?
TAM, everolimus ? tamoxifen; EXE, exemestane; FEC, 5 fluo-
rouracil, epirubicin, cyclophosphamide; FU ? VIN, fluo-
rouracil ? vinorelbine; GEM ? PAC, gemcitabine ? paclitaxel;
LIP DOX, liposomal doxorubicin; MA, megestrol acetate; MITOX,
mitoxantrone; NAB-PAC, nab-paclitaxel 150 mg/m2; PAC, pacli-
taxel; PAC ? SOR, paclitaxel ? sorafenib; PAC ? SUN, suni-
tinib ? paclitaxel; PLB, placebo; TAM, tamoxifen; VIN ? CAP,
vinorelbine ? capecitabine. b NMA results for the RRs. Values
reported are odds ratios of each chemotherapy-based treatment versus
the combination everolimus plus exemestane. Central dots represent
posterior medians, triangles and crosses represent posterior means;
thin lines are 95 % credible intervals, while thicker ones are 80 %
credible intervals. The symbol of the triangle highlights the combi-
nation EXE/EVE is significantly superior. BEVA ? CAP, beva-
cizumab ? capecitabine; BEVA ? DOC, bevacizumab 15 mg/
kg ? docetaxel; BEVA ? GEM ? PAC, paclitaxel ? beva-
cizumab ? gemcitabine; BEVA ? IXA, ixabepilone (16 mg/m2-
) ? bevacizumab; BEVA ? PAC, bevacizumab ? paclitaxel; CAP,
capecitabine; CAP ? DOC, capecitabine ? docetaxel; CAP ? E-
PI ? PAC, epirubicin ? paclitaxel ? capecitabine; CAP ? PAC,
capecitabine ? paclitaxel; CAP ? SOR, capecitabine ? sorafenib;
CAP ? SUN, capecitabine ? sunitinib; CARBO ? PAC, pacli-
taxel ? carboplatin; CMF, cyclophosphamide, methotrexate, 5 fluo-
rouracil; CYC ? EPI, epirubicin ? cyclophosphamide; DOC,
docetaxel; DOC ? EPI, docetaxel ? epirubicin; DOC ? GEM, doc-
etaxel ? gemcitabine; DOC ? SUN, docetaxel ? sunitinib;
DOC ? VAN, vandetanib ? docetaxel; DOX, doxorubicin; EPI ? -
GEM ? PAC, gemcitabine ? epirubicin ? paclitaxel; EPI ? PAC,
epirubicin ? paclitaxel; EVE ? TAM, everolimus ? tamoxifen;
EXE, exemestane; FEC, 5 fluorouracil, epirubicin, cyclophos-
phamide; FU ? VIN, fluorouracil ? vinorelbine; GEM ? PAC,
gemcitabine ? paclitaxel; MA, megestrol acetate; MITOX, mitox-
antrone; NAB-PAC, nab-paclitaxel 150 mg/m2; PAC, paclitaxel;
PAC ? SOR, paclitaxel ? sorafenib; PAC ? SUN, sunitinib ? pa-
clitaxel; PLB, placebo; TAM, tamoxifen. c NMA results for the HRs.
Values reported are hazard ratios of the combination everolimus plus
exemestane versus each one of the other treatments. Central dots
represent posterior medians, triangles and crosses represent posterior
means; thin lines are 95 % credible intervals, while thicker ones are
80 % credible intervals. The symbol of the triangle highlights the
combination EXE/EVE is significantly superior. BEVA ? CAP,
bevacizumab ? capecitabine; BEVA ? DOC, bevacizumab 15 mg/
kg ? docetaxel; BEVA ? GEM ? PAC, paclitaxel ? beva-
cizumab ? gemcitabine; BEVA ? IXA, ixabepilone (16 mg/m2-
) ? bevacizumab; BEVA ? PAC, bevacizumab ? paclitaxel; CAP,
capecitabine; CAP ? DOC, capecitabine ? docetaxel; CAP ? E-
PI ? PAC, epirubicin ? paclitaxel ? capecitabine; CAP ? PAC,
capecitabine ? paclitaxel; CAP ? SOR, capecitabine ? sorafenib;
CAP ? SUN, capecitabine ? sunitinib; CARBO ? PAC, pacli-
taxel ? carboplatin; CMF, cyclophosphamide, methotrexate, 5 fluo-
rouracil; CYC ? EPI, epirubicin ? cyclophosphamide; DOC,
docetaxel; DOC ? EPI, docetaxel ? epirubicin; DOC ? GEM, doc-
etaxel ? gemcitabine; DOC ? SUN, docetaxel ? sunitinib;
DOC ? VAN, vandetanib ? docetaxel; DOX, doxorubicin; EPI ? -
GEM ? PAC, gemcitabine ? epirubicin ? paclitaxel; EPI ? PAC,
epirubicin ? paclitaxel; EVE ? TAM, everolimus ? tamoxifen;
EXE, exemestane; FEC, 5 fluorouracil, epirubicin, cyclophos-
phamide; FU ? VIN, fluorouracil ? vinorelbine; GEM ? PAC,
gemcitabine ? paclitaxel; MA, megestrol acetate; MITOX, mitox-
antrone; NAB-PAC, nab-paclitaxel 150 mg/m2; PAC, paclitaxel;
PAC ? SOR, paclitaxel ? sorafenib; PAC ? SUN, sunitinib ? pa-
clitaxel; PLB, placebo; TAM, tamoxifen
c
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cases, PFS and tumor RR were assessed locally without an
independent review and one study reported that robust
assessment of PFS was not feasible due to the lack of
regular imaging. Twenty-six studies showed a bias in the
selection of the results since they did not report overall
survival (OS) or PFS curves or related HRs. Regarding the
assessment of adverse events, almost all of the studies did
not report clearly if measures were taken to ensure the
‘‘blindness’’ of the evaluators.
Exploratory evaluation of adverse events
The studies included in the NMA reported the adverse
events [18] heterogeneously, thus we have focused on the
reported AEs of grade 3/4 only, for the combination of
EXE/EVE and for the other chemotherapy-based trials. A
systematic assessment of the safety of EXE/EVE versus all
the other treatments through a NMA was not feasible since
few studies did not report information on AEs at all or
explicitly on AEs of grade 3/4 or for the considered ther-
apeutic schemes, leading to a limited connected network of
studies.
The analysis of AEs has been restricted to an explora-
tory evaluation of the percentages of patients affected. The
data are shown in Table 4 separately for biochemical
changes and hematologic and non hematologic events. In
case different studies reported different percentages for the
same treatment, ranges (min–max) were reported. The
combination of EXE/EVE showed less AEs if compared to
chemotherapy-based treatment, especially versus regimens
containing nab-paclitaxel or bevacizumab.
Discussions
Even with modern therapies, very few patients are cured of
MBC; treatment is palliative with the goals of symptom
relief and possibly prolongation of life. The challenge for
the clinicians is to balance treatment-related toxicity with
the likelihood of benefit and cancer-related symptom relief
from therapy. For these reasons, endocrine therapy should
be adopted as the preferred initial treatment for ER?ve
MBC as mentioned in international guidelines [19]. How-
ever, Andre et al., although endocrine therapy is predom-
inantly used (69 %), showed that the clinical choice of
treatment in first line is still a matter of discussion between
chemotherapy versus endocrine therapy in Europe [20].
AIs have become the most frequently used first-line
151050
NAB-PAC
DOC+VAN
BEVA+DOC
BEVA+GEM+PAC
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DOC+SUN
DOX
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endocrine therapy of MBC in postmenopausal women
because they increase PFS compared with tamoxifen [21,
22]. Recently, the combination of EXE/EVE showed a
significant improvement of PFS in MBC compared to EVE
alone. Bachelot et al. also showed in a NMA that the
combination of EXE/EVE has higher PFS/TTP compared
to fulvestrant alone [10].
Partridge et al. stated the expert consensus opinion that
endocrine therapy is preferable to chemotherapy in the
early lines of MBC treatment [11]; however, few ran-
domized clinical trials compared directly these two dif-
ferent treatment modalities. Based on the report recently
published by Cope et al. [23] about the feasibility of per-
forming NMA of RCTs to synthesize direct and indirect
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vinorelbine ? capecitabine
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Table 4 List of adverse events [18] of grade 3/4 from the studies included in the NMA
Tamoxifena CMFb Capecitabinec FECd Exemestanee Exemestane ? everolimusf
Non hematologic events
Alopecia 33.3–66
Anorexia 1.1–4
Arthralgia 1.0
Asthenia 3.0 5.6 3.0
Cardiac dysrhythmia 1.1 1.0 1.6
Cardiac dysfunction/infarction 0.5 2.0
Cardiotoxicity 3.1
Cerebrovascular ischemia
Deep venous thrombosis 0.5
Depression 0.5
Diarrhea 2–5.5 4–10 0.8–1 1.0 2.0
Dyspnea 2.6 2–4 1–1.6 4.0
Edema 1.1 1.1 1.0
Fatigue/malaise/lethargy 1.1–11 6.4 1–3 1–1.1 3.0
Febrile neutropenia 8–10.1 11.0
Gastrointestinal 0.5
Hand–foot skin reaction/hand–foot
syndrome
24.0
Hepatic toxicity 3.1
Hypertension 3.2 1–2 3.3
Infection 5.0 4–8.3 3–5 1.1
Lung function 7.0
Mucositis 15.0 1–4 0.8–12
Musculoskeletal 1.1
Nausea/vomiting 0.5–4 3.7–14 4.0 16.6–23 1.0
Neurologic, sensory 1.1 4.0
Pain 9–18 1–3 9.0 1–6.5
Phlebitis 0.5
Pneumonitis 4.0 3.0
Skin reaction 3.0 1.0
Stomatitis 5.5 2.0 2–4.2 1.0 8.0
Thrombosis or embolism
Vaginal bleeding 0.5
Weight loss 1.1
Weight gain 0.5 1.1
Hematologic events
Decreased hemoglobin/anemia 1.1–4 3.7–9 4.0 1.4–12 1.1 6.0
Decreased lymphocyte count 4.0
Thrombocytopenia 0.5 2.8–6.0 1.4–7.0 1.6 2.0
Neutropenia 25.7 3–4 59.7–83.9 1.1
Leukopenia 4.6–58 33.3–66.0
Proteinuria
Biochemical changes
Bilirubin 1.6 3.3
Alanine aminotransferase level increased 4.2 2.0–7.7
Aspartate aminotransferase level increased 4.8 1.0–4.9 3.0
Creatinine 1.6
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Table 4 continued
Epirubicin ?
gemcitabine ?
paclitaxelg
Bevacizumab ?
paclitaxelh
Docetaxeli Paclitaxelj Epirubicin ?
paclitaxelk
Bevacizumab ?
docetaxell
Carboplatin ?
paclitaxelm
Non hematologic events
Alopecia 66.4 3.9–44 22–44 71.0 3.6 67.0
Anorexia 0.9––3 0.3 2.0
Arthralgia 3.2 1.4–2.7 6.0
Asthenia 7–20.7 5.0 6.9
Cardiac dysrhythmia
Cardiac dysfunction/
infarction
0.8–1.1 0.3–1
Cardiotoxicity 3.3 2.0 1.8–3
Cerebrovascular
ischemia
1.9
Deep venous thrombosis
Depression
Diarrhea 4.1 3.1–4 3–7 0.5–1.9 0.6–5 6.5
Dyspnea 1.7–2 1.0 1.0 2.8
Edema 2–6.8 0.5 0.4
Fatigue/malaise/lethargy 6–9.6 5.2–19 1.2–6 4.2–6 6.5
Febrile neutropenia 0.8 11.3–14.9 1.2–7 3.6–17 16.2
Gastrointestinal 0.9–3
Hand–foot skin reaction/
hand–foot syndrome
1.0 1.0
Hepatic toxicity 4.1
Hypertension 1.1–14.8 1.3 4.5
Infection 6–9.3 2–9.9 1.8–4 4.2–13 0.4 2.0
Lung function
Mucositis 13.1 0.4–2 2–6 4.9
Musculoskeletal
Nausea/vomiting 13.1 2.1–6 2.6–8.6 2–3.2 3–10 4.0
Neurologic, sensory 4.9 8.5–25 3.9–12.2 4.1–17.7 2.4–10 6.1 5.0
Pain 2.0 1–6.3 1–6.4 4.2–14 8.4 1.0
Phlebitis
Pneumonitis
Skin reaction 3.3 2–4.5 8.9
Stomatitis 1–2.1 0.4–10.8 0.4–1 3.2
Thrombosis or embolism 2.1 3.0 1.5 4.0 2.0
Vaginal bleeding
Weight loss
Weight gain
Hematologic events
Decreased hemoglobin/
anemia
21.1 6.3 2–10.4 7.3 1.8 2.0 1.0
Decreased lymphocyte
count
Thrombocytopenia 28.5 1–4.6 0.3–2.8 3.0 3.0
Neutropenia 92.7 21.9 3–94 0.3–54.5 54.8 19.8 13.0
Leukopenia 9.4 4.3–22 6.0 20.4–40.6 5.3 2.0
Proteinuria 1.1–3.5 2.0
112 Breast Cancer Res Treat (2015) 152:95–117
123
Author's personal copy
evidence for alternative treatments for a specific disease
population, we have decided to use the NMA approach and
the meta-analysis of the NNT for the indirect comparison
of clinical evidence of EXE/EVE versus any chemothera-
pies with published data as first or second line of treatment
for ER?ve MBC.
Assuming that PFS is a clinically important measure of
drug efficacy [24]; in our analysis, the EXE/EVEcombination
was at least as efficacious as any chemotherapy given alone or
in combination. This observation is reproduced in theNMAof
HR for PFS/TTP and in theNMA for RR. The analysis did not
show any clear evidence for the other chemotherapies to be
better than the combination of EXE/EVE. It is projected that
EXE/EVE is superior to CMF (95 % CrIs 0.96–17.25) or to
capecitabine (95 %CrIs 1.24–13.89) in terms ofmedian PFS/
TTP or HR of PFS/TTP, respectively. It showed also superi-
ority to single-agent capecitabine (95 % CrIs 1.41–16.55)
(95 % CrIs 0.01–0.43) in term of HR of PFS/TTP or RR,
respectively. EXE/EVE also appeared to be more efficacious
than FEC (95 %CrIs 0.01–0.51) for RR and equal for HR and
for PFS/TTP. In the NMA analysis, EXE/EVE is projected to
be as efficacious as any of the chemotherapy regimens con-
taining a taxane [17, 25]. The combination was slightly infe-
rior to nab-paclitaxel as second-line treatment of MBC [26,
27] (95 % CrIs 0.16–3.46). However, it is known the taxane-
combined regimens are superior to taxane inmonotherapy for
TTP [28], PFS, and RR rates [29, 30], and in OS [31], even
further evaluations are required with regards to estrogen
receptor status [32].
In the NMA analysis, all the RCTs were considered, even
those with the combination of target therapies, such as beva-
cizumab, sunitinib, sorafenib, etc. So far, no targeted therapy
has shown to enhance chemotherapy outcome in HER2-ve
breast cancer except for bevacizumab [33, 34].The additionof
bevacizumab to chemotherapy, such as taxane or capecita-
bine, has demonstrated improvements in RR and PFS in both
first- and second-line therapy [33–35], which are considered
surrogate parameters for OS [36]. However, bevacizumab has
no significant impact on OS or HRQoL, which are indicators
of a direct patient benefit. For this reason, the clinical value of
Table 4 continued
Epirubicin ?
gemcitabine ?
paclitaxelg
Bevacizumab ?
paclitaxelh
Docetaxeli Paclitaxelj Epirubicin ?
paclitaxelk
Bevacizumab ?
docetaxell
Carboplatin ?
paclitaxelm
Biochemical changes
Bilirubin
Alanine
aminotransferase level
increased
0.4
Aspartate
aminotransferase level
increased
1.4 0.6
Creatinine
The reported numbers are the proportions of occurrence for each single AE
CMF cyclophosphamide, methotrexate, 5 fluorouracil, FEC 5 fluorouracil, epirubicin, cyclophosphamide
a Bachelot (2012) and Paridaens (2008)
b Ackland (2001) and Stockler (2011)
c Baselga (2012) and Crown (2013)
d Ackland (2001), Bonneterre (2004), Heidemann (2002) and Zielinski (2005)
e Baselga (2012) and Paridaens (2008)
f Baselga (2012/2013)
g Zielinski (2005)
h Miller (2007), Brufsky (2011), Rugo (2013) and Martin (2011)
i Bergh (2012), Bonneterre (2002), Jones (2005), Miles (2010), Papadimitriou (2009) and Gradishar(2009/2012)
j Albain (2008), Fountzilas (2009), Gradishar (2013), Miller (2007), Paridaens (2000) and Jones (2005)
k Hatschek (2012), Langley (2005) and Luck (2013)
k Miles (2010)
m Fountzilas (2009)
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bevacizumab for MBC remains controversial. The results
observed with the combination of EXE/EVE appears to be
superior or at least as efficacious as the results with the com-
bination of bevacizumab and capecitabine or taxane as
described in the NMA for RR, HR of PFS/TTP, and PFS/TTP
curves. Moreover, the combination showed to have a signifi-
cant positive impact on HRQoL of the patients although
associatedwithmoderate butmanageable side effects [37].As
shown in the expanded access BALLET trial, the onset of the
adverse events was mainly confined into the first 3 months of
treatment with regards to the EXE/EVE regimen with a
reduction in terms of number of events during the following
months [38]. On the counterpart, the AEs related to
chemotherapy last for all the duration of treatment with an
increased grade of toxicity in case of a maintenance scheme
[39].
In the meta-analysis by Gennari et al., it has been shown
that longer planned treatment durations have been associ-
ated with significant increases in OS and PFS [40]. The
NMA of NNT showed clearly that the combination of EVE
plus EXE provides an increased benefit when compared to
chemotherapy over time.
As the choice of the treatment in MBC is determined by
multiple factors such as the prior therapy, the toxicity, the
performance status, the comorbid conditions, the patient
preference, and the impact on patients’ benefit such as OS
or HRQoL, the combination of EXE/EVE could be taken
into account, not only for its manageability, but also when
the clinician would have to plan a longer duration of the
therapy.
However, performing this NMA, we have found three
limitations: (1) the combination of two different outcome
measures such as the PFS and the TTP. Although PFS and
TTP can have dissimilar results because deaths are not
typically included in TTP, the two outcome measures had
overlapping criteria for disease-specific deaths; therefore,
the majority of on study deaths were assumed to be dis-
ease-specific, and the analysis assumed that PFS and TTP
would be the same, (2) the data related to the HRs are
based on the proportional hazards assumption of a constant
ratio of the hazard rates for the two compared treatments.
Many times this assumption is implausible, because the
data provide evidence of an opposite situation, i.e., a ratio
of the hazard rates that changes with time, thus we had to
add a NMA involving the whole PFS/TTP curves rather
than their HR summary measure, (3) in the earliest
chemotherapy-based trials, the modern classification of BC
was not used; therefore up to 20 % of the enrolled patients
may be HER2?ve. However, the combination of EXE/
EVE is confined to ER?ve/HER2-ve MBC, whereas the
chemotherapy-based regimens were administered in MBC
without any specific report to the ER and HER2 status.
Only few authors reported the RR or the PFS-related HRs
data with regards to ER or HER2 expression, thus we
assumed that the two population could be comparable even
they are strictly not. Thus, this indirect comparison is
subject to caution.
In conclusion, this indirect treatment comparison sug-
gests that EVE in combination with EXE may be more
efficacious (or at least as beneficial as) than some of the
chemotherapy agents alone or in combination as poly-
chemotherapy or in association with targeted therapies in
postmenopausal women with HR?ve/HER2-ve advanced
breast cancer for their first/second line of treatment.
Moreover, the combination seems to have less AEs or more
manageable grade 3/4 treatment-related toxicities in
agreement with the recent analyses where hormone-therapy
was associated with better patient-reported outcomes than
chemotherapy in first-line MBC management, and these
findings should be taken into consideration while making
treatment decisions for ER?ve/HER2-ve MBC [41].
Future trials should be based on the randomization com-
paring the best endocrine-based therapy available versus
chemotherapy-based treatment maybe combined with most
promising targeted agents as first-line treatment for only
ER?ve/HER2-ve MBC (as in the PEARL study and
BOLERO-6 study). A selective combination of these thera-
pies should be evaluated in order to define an optimal treat-
ment strategy in terms of outcome and also HRQoL.
However, given the heterogeneity of breast cancer, even
when restricted to specific subtypes, it is also possible that
the same best therapeutical approach for most patients does
not exist. Instead, in the genomic era, the molecular diag-
nosis of the tumor may potentially allow in the future to
select a specific drug which will best fit with the specific
disease of any single patient.
Key issues
• Several chemotherapy regimens are used as first-line
therapy for postmenopausal women with ER?ve MBC.
Up to now, results of randomized trials comparing
chemotherapy with endocrine therapy in combination
with targeted therapy are not yet available but expected
in the near future (ex. BOLERO-6).
• The NMA indirectly compares the efficacy and safety
of EXE/EVE with chemotherapy agents as first- or
second-line therapy for ER?ve/HER2-ve MBC.
• Concerning the analysis of PFS/TTP curves or ORR or
HRs, the combination of EXE and EVE is more
efficacious than (or at least as beneficial as) some of the
chemotherapy agents alone or in combination or in
association with targeted therapies in postmenopausal
women with ER?ve/HER2-ve advanced breast cancer
for their first/second line of treatment.
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• The analysis on the NNT revealed that EXE/EVE at 3,
9, and 15 months is more beneficial with regards to
several chemotherapy-based regimes.
• An exploratory evaluation of the safety of EXE/EVE
versus all the other treatments showed that EXE/EVE
reported less adverse events if compared to chemother-
apy-based treatments.
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Methods 
 
A systematic literature search was performed in May 2014 to identify published RCTs 
evaluating the clinical efficacy of everolimus (EVE) plus exemestane (EXE) versus 
chemotherapy (CT) or chemotherapy plus biological (CT + BIO) in hormone receptor (ER) 
positive and human epidermal growth factor 2 (HER2) negative MBC in first or second 
line of treatment. 
PFS has been selected as the primary endpoint based on the common definition that PFS 
was the time from randomization to either death or disease progression, whichever occurs 
first. The lack of follow-up information in most of the papers was the main reason not to 
consider the overall survival (OS) as the primary endpoint. As reported in several studies, 
the use of PFS is mixed up with Time To Progression (TTP) [16], thus it was decided to 
use PFS and TTP as the same variable for the same endpoint. However, because PFS/TTP 
are surrogate endpoints, an improvement in PFS/TTP alone was not considered as 
sufficient evidence of a patients’ benefit; thus, the Tumor Response Rate (RR), defined 
accordingly to the RECIST Criteria, was added into the analysis as a variable for the 
evaluation of patients’ benefit. 
Search strategy 
The search following the recommendations of The Cochrane Collaboration was performed 
in order to identify all relevant, published and unpublished trials. Due to the relatively 
	 2	
recent availability of studies involving everolimus-based therapies for metastatic breast 
cancer and the new chemotherapeutical schedule and/or compounds used in clinical 
routine, a literature search starting from year 2000 was considered sufficient for the 
purpose of this review. The search strategy was based by using a combination of subject 
headings and text words relating to everolimus, chemotherapy, biological/target therapies 
and metastatic breast cancer. In particular, the combination of disease, treatment, and study 
design terms in both studies’ titles or abstracts was: 
• disease terms: breast or mammary and disease descriptors (cancer, neoplasm, oncology, 
tumor, malignancy, carcinoma, adenocarcinoma, or sarcoma) as well as metastasis, 
advanced, secondary, recurrent, inoperable, disseminated, or incurable. 
• treatment terms: chemotherapy, endocrine therapy, everolimus (as well as Afinitor, 
SDZ-RAD, rad001, or 159351-69-6), cyclophosphamide, methotrexate, fluorouracil, 
doxorubicin, mitoxantrone, epirubicin, paclitaxel, docetaxel, liposomal doxorubicin, 
nab-paclitaxel, pegylated, liposomal doxorubicin, eribulin, capecitabine, vinorelbine. 
• RCT terms: British Medical Journal filter for RCTs. 
The electronic databases Pubmed®, EMBASE®, Cochrane Central Register of Clinical 
Trials and Web of Science were used for the search. 
Three reviewers independently evaluated each identified single study against the 
established predetermined criteria. Details were extracted on study design, study population 
characteristics, and interventions. The hazard ratios and associated 95% confidence 
intervals were extracted for PFS/TTP where reported. 
Statistical Analysis 
A Bayesian Network Meta Analysis (NMA) framework was used for each endpoints 
considered: the tumor response rate(RR), the hazard ratio (HR) of PFS/TTP and the whole 
PFS/TTP curve [17]. In Figure S1, the scanned survival proportions are presented by study 
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meta-analysis of the Number Needed to Treat (NNT) for EXE/EVE versus each one of the 
other chemotherapy-based regimes was also performed [18]. 
All models have been implemented with both fixed and random effects to identify the best 
fit to the data. The parameters of the different models were estimated using a Markov 
Chain Monte Carlo (MCMC) method as implemented in the WinBUGS software package 
[19]. For all the analyses, the WinBUGS sampler, using two chains, was run for 500,000 
iterations that were discarded as ‘burn-in’, and the model was run for a further 2,500,000 
iterations on which inferences were based. A thinning rate of 100 iterations was used to 
reduce autocorrelation of the sampled values [20], thus leaving 25,000 iterations per chain 
to use for estimation and inference. Convergence of the chains was confirmed by the 
Gelman-Rubin statistic and by inspection of the trace plots. The Deviance Information 
Criterion was used to compare the goodness-of-fit of different models [22]. DIC provides a 
measure of model fit that penalizes model complexity. The model with the lowest DIC was 
considered the model providing the “best” fit to the data. 
Quality assessments 
The evaluation of the presence of bias in the studies included into the analysis is therefore 
an essential component of a review or meta-analysis. Internal validity of eligible studies 
was assessed according to the Cochrane Collaboration’s ’Risk of Bias’ tool in Review 
Manager (RevMan 5, http://tech.cochrane.org/revman). The risk of bias and judged bias 
were described in the following specific domains: sequence generation; allocation 
concealment; blinding of participants and personnel and outcome assessors; blinding of 
outcome assessment: PFS/TTP and response; blinding of outcome assessment: Toxicity; 
incomplete outcome data: PFS and OS; incomplete outcome data: Response; incomplete 
outcome data: Toxicities; selective outcome reporting. 
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Table S1: Deviance information criterion (DIC) values for the models of the whole 
PFS/TTP curves. 
 Fixed effects model Random effects model 
Weibull model 
(Ouwens et al, 2011) 7,330.92 7,331.01 
Second-order fractional 
polynomial with !1 = −2 and !2 = 1 
(Jansen, 2011) 
7,164.68 7,168.05 
 
  
	 5	
 
Table S2A: NMA results for the PFS/TTP curves. Values reported are differences in 
the expected PFS/TTP (in months) for the combination of everolimus plus exemestane 
versus each one of the chemotherapy-based treatments. It provides the posterior means 
and medians, together with the 80 and 95% CrIs. If the 95% CrI does not include the 
value 0, this suggests that there is evidence of a difference between the treatments (in 
gray when significantly superior). 
Comparator Number of trials 
Posterior 
mean 
Posterior 
median 95% credible interval 
Capecitabine+Sunitinib 1 9.79 9.49 3.79 17.74 
CMF 4 8.97 8.87 0.96 17.25 
Megestrol Acetate 2 6.91 6.31 3.2 14.4 
Capecitabine 5 8.59 8.72 -1.44 17.13 
Mitoxantrone 2 7.71 7.75 -1.78 16.24 
Tamoxifen 2 6.04 5.58 1.37 13.87 
BMF 1 7.81 8.06 -3.99 16.47 
FEC 4 7.2 7.25 -3.63 15.98 
Docetaxel+Epirubicin 2 6.1 6.08 -4.86 14.81 
Gemcitabine+Epirubicin+Paclitaxel 1 5.95 6.22 -5.97 14.63 
Bevacizumab 15 mg/kg+Docetaxel 1 6.45 6.83 -8.07 15.81 
Sunitinib+Paclitaxel 1 6.28 7.19 -12.22 16.6 
Exemestane 3 3.89 3.91 -5.24 13.8 
Vinorelbine+Capecitabine 1 6.82 9.2 -15.23 18.05 
Paclitaxel 5 5.58 7.35 -14.49 17.09 
Capecitabine+Sorafenib 1 4.03 5.44 -14.67 15.42 
Liposomal Doxorubicin 1 4.33 5.95 -19.02 16.39 
Gemcitabine+Paclitaxel 2 3.86 5.67 -17.88 16.1 
Everolimus+Tamoxifen 1 -3.1 -3 -13.93 7.55 
Docetaxel+Sunitinib 1 3.07 5.25 -20.89 16.16 
Paclitaxel+Sorafenib 1 3.03 5.41 -19.94 16.29 
Fluorouracil+Vinorelbine 1 3.21 5.69 -20.65 16.38 
Doxorubicin 1 2.6 4.71 -21.71 15.81 
Placebo 1 2.88 5.53 -22.16 16.54 
Docetaxel+Gemcitabine 4 2.33 4.75 -21.02 15.93 
Docetaxel 7 1.95 4.58 -22.13 16.18 
Bevacizumab+Paclitaxel 4 1.43 4.1 -22.61 16.06 
Capecitabine+Docetaxel 4 -0.15 2.93 -26.08 15.65 
Bevacizumab+Capecitabine 1 -2.59 0.68 -28.54 14.94 
Paclitaxel+Bevacizumab+Gemcitabine 1 -2.08 1.38 -30.27 15.72 
Nab-Paclitaxel 150 mg/m2 1 -4.68 -1.1 -32.38 14.61 
BMF: BENDAMUSTINE HYDROCHLORIDE, METHOTREXATE, 5 FLUOROURACIL 
CMF: CYCLOPHOSPHAMIDE, METHOTREXATE, 5 FLUOROURACIL 
FEC: 5 FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE 
 
 
Table S2B: NMA results for the RRs. Numbers reported are odds ratios of each 
chemotherapy-based treatment versus the combination everolimus plus exemestane (in 
gray when significantly superior). 
Comparator Number of trials 
Posterior 
mean 
Posterior 
median 95% credible interval 
Mitoxantrone 2 0.08 0.05 0.01 0.28 
Tamoxifen 2 0.08 0.07 0.02 0.19 
CMF 2 0.09 0.06 0.01 0.35 
Capecitabine 4 0.1 0.06 0.01 0.43 
Capecitabine+Sunitinib 1 0.11 0.07 0.01 0.49 
Megestrol Acetate 2 0.12 0.11 0.04 0.29 
FEC 4 0.13 0.09 0.01 0.51 
Capecitabine+Sorafenib 1 0.15 0.09 0.01 0.66 
Exemestane 3 0.15 0.14 0.05 0.33 
Everolimus+Tamoxifen 1 0.19 0.16 0.04 0.55 
Bevacizumab+Capecitabine 1 0.21 0.13 0.02 0.88 
Gemcitabine+Epirubicin+Paclitaxel 1 0.21 0.14 0.02 0.84 
Epirubicin+Cyclophosphamide 1 0.24 0.12 0.01 1.25 
Paclitaxel+Carboplatin 2 0.27 0.13 0.01 1.37 
Epirubicin+Paclitaxel 4 0.36 0.17 0.02 1.86 
Paclitaxel 6 0.41 0.21 0.02 2.03 
Docetaxel+Epirubicin 2 0.42 0.26 0.03 1.76 
Capecitabine+Paclitaxel 1 0.45 0.22 0.02 2.42 
Fluorouracil+Vinorelbine 1 0.51 0.25 0.02 2.62 
Epirubicin+Paclitaxel+Capecitabine 1 0.53 0.25 0.02 2.83 
Ixabepilone (16 mg/m2)+Bevacizumab 1 0.55 0.25 0.02 2.91 
Docetaxel 7 0.58 0.3 0.03 2.89 
Placebo 1 0.63 0.31 0.03 3.21 
Paclitaxel+Sorafenib 1 0.74 0.37 0.03 3.74 
Gemcitabine+Paclitaxel 2 0.8 0.42 0.04 3.93 
Doxorubicin 1 0.87 0.44 0.04 4.41 
Bevacizumab+Paclitaxel 5 0.9 0.5 0.05 4.18 
Capecitabine+Docetaxel 2 0.9 0.46 0.04 4.52 
Docetaxel+Gemcitabine 3 0.91 0.49 0.05 4.38 
Sunitinib+Paclitaxel 1 0.92 0.46 0.04 4.7 
Docetaxel+Sunitinib 1 0.99 0.5 0.05 5.01 
Nab-Paclitaxel 150 mg/m2 1 1.08 0.52 0.05 5.65 
Bevacizumab 15 mg/kg+Docetaxel 1 1.2 0.61 0.06 6.12 
Paclitaxel+Bevacizumab+Gemcitabine 1 1.43 0.7 0.06 7.48 
Vandetanib+Docetaxel 1 2.43 1.01 0.07 13.78 
CMF: CYCLOPHOSPHAMIDE, METHOTREXATE, 5 FLUOROURACIL 
FEC: 5 FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE 
 
 
Table S2C: NMA results for the HRs of PFS/TTP. Numbers reported are hazard ratios 
of the combination everolimus plus exemestane versus each one of chemotherapy-
based treatments (in grey when significantly superior). 
Comparator Number of trials 
Posterior 
mean 
Posterior 
median 95% credible interval 
Capecitabine+Sunitinib 1 7.21 5.81 1.67 20.70 
Capecitabine 4 5.86 4.78 1.41 16.55 
Epirubicin+Paclitaxel+Capecitabine 1 5.21 3.86 0.86 17.71 
CMF 2 5.00 4.12 1.24 13.89 
Capecitabine+Paclitaxel 1 4.43 3.27 0.72 15.02 
Epirubicin+Paclitaxel 4 4.34 3.24 0.73 14.66 
Epirubicin+Cyclophosphamide 1 4.07 3.02 0.68 13.70 
Bevacizumab+Capecitabine 1 4.06 3.30 0.95 11.58 
Mitoxantrone 2 3.77 3.17 1.00 10.18 
Capecitabine+Sorafenib 1 3.71 2.96 0.81 10.98 
FEC 4 3.63 3.01 0.93 9.98 
Gemcitabine+Epirubicin+Paclitaxel 1 3.30 2.70 0.80 9.26 
Paclitaxel+Carboplatin 2 3.28 2.48 0.57 10.95 
Megestrol Acetate 2 3.17 3.14 2.29 4.29 
Tamoxifen 2 3.17 3.14 2.39 4.13 
Sunitinib+Paclitaxel 1 3.16 2.24 0.46 11.29 
Paclitaxel 6 3.05 2.31 0.55 10.14 
Docetaxel+Epirubicin 2 2.98 2.38 0.65 8.89 
Exemestane 3 2.65 2.63 2.11 3.28 
Placebo 1 2.47 1.74 0.35 8.85 
Paclitaxel+Sorafenib 1 2.44 1.82 0.41 8.34 
Ixabepilone (16 mg/m2)+Bevacizumab 1 2.41 1.69 0.34 8.71 
Fluorouracil+Vinorelbine 1 2.32 1.73 0.39 7.85 
Docetaxel+Gemcitabine 3 2.21 1.69 0.41 7.15 
Gemcitabine+Paclitaxel 2 2.06 1.57 0.37 6.81 
Docetaxel 7 1.94 1.47 0.35 6.45 
Bevacizumab+Paclitaxel 5 1.91 1.38 0.30 6.69 
Capecitabine+Docetaxel 2 1.83 1.41 0.35 5.86 
Doxorubicin 1 1.81 1.36 0.32 6.08 
Docetaxel+Sunitinib 1 1.80 1.35 0.31 6.01 
Everolimus+Tamoxifen 1 1.75 1.70 1.01 2.83 
Paclitaxel+Bevacizumab+Gemcitabine 1 1.59 1.13 0.23 5.69 
Bevacizumab 15 mg/kg+Docetaxel 1 1.50 1.13 0.26 5.05 
Vandetanib+Docetaxel 1 1.37 1.01 0.22 4.62 
Nab-Paclitaxel 150 mg/m2 1 0.99 0.72 0.16 3.46 
CMF: CYCLOPHOSPHAMIDE, METHOTREXATE, 5 FLUOROURACIL 
FEC: 5 FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE 
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Figure S1A: Progression-free survival as observed in individual studies by trial. 
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Figure S1B: Progression-free survival as observed in individual studies by treatment. 
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Figure S2: Risk of bias summary: reviewers’ judgement about each risk of bias item 
for each included study. Both the 80 and 95% CrIs are provided; posterior means are 
also reported using triangles for those treatment whose 95% CrI does not include the 
value 1, and using crosses for those including the value 1. If the 95% CrI does not 
include the value 1, this suggests that there is evidence of a difference between the 
treatments. 
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Figure S3: Risk of bias graph: review authors’ judgement about each risk of bias item 
presented as percentage of all included studies. Both the 80 and 95% CrIs are provided; 
posterior means are also reported using triangles for those treatment whose 95% CrI does not 
include the value 1, and using crosses for those including the value 1. If the 95% CrI does not 
include the value 1, this suggests that there is evidence of a difference between the treatments. 	
